NEW YORK — Prenetics Global Limited (NASDAQ:PRE), parent of the IM8 premium health and longevity brand, revealed record financial results for the fourth quarter and full year ended Dec. 31, 2025, according to a company statement released Wednesday.

The results cap a year of aggressive transformation for Prenetics. Executives divested non-core assets including ACT Genomics for up to $72 million in cash — with $46 million in gross proceeds to the company — the Europa distribution business for up to $13 million in stock, and its Insighta stake to Tencent for $70 million. Those moves left Prenetics with about $171 million in adjusted liquidity as of Feb. 15, 2026, and zero debt.

IM8 drove the numbers. The brand, co-founded with David Beckham, generated $60.1 million in 2025 revenue. It hit $10 million in monthly sales in December, pushing annual recurring revenue to $120 million. That marks one of the fastest ramps in the global supplements sector, company officials said.

Fourth-quarter revenue climbed 55% from the prior quarter to $36.6 million. IM8’s gross margin dipped to 60% in the period from 62% in the third quarter, hit by holiday freight costs and rising international sales. Prenetics aims to hold that level steady through 2026.

Customer acquisition improved too. The payback period for IM8 shortened to 3.5 months in the fourth quarter from 3.9 months earlier, thanks to a new quarterly subscription option launched in the U.S. in December 2025 and rolled out globally in January 2026.

Revenue spread across borders. The U.S. led with $23.8 million, or 39.7% of IM8 sales. Canada followed at $8.8 million (14.7%), the U.K. with $7.7 million (12.8%), Australia at $3.2 million (5.3%) and Singapore with $2.4 million (4%). Shipments reached more than 30 countries, with over 60% of revenue from outside the U.S.

Unit economics stayed strong. Blended average order value hit about $110 for the year, climbing to $133 in the fourth quarter and $233 for new customers in January and February 2026. Day-one customer acquisition cost recovery stood at 55%, with a projected 24-month lifetime value to CAC ratio of 3x.

Quarterly subscriptions now dominate new sign-ups. Roughly half of Beckham Stack buyers and over a third of Essentials customers chose the three-month prepay option in early 2026. That shift boosts upfront cash, cuts logistics costs and locks in renewals, executives noted.

Prenetics leaned into sports marketing. In June 2025, world No. 1 tennis player Aryna Sabalenka, a four-time Grand Slam winner, joined as a global ambassador and shareholder. This month, Formula 1 rising star Ollie Bearman signed on in the same role, burnishing IM8’s elite performance image.

The company will discuss results on an earnings call Feb. 18, 2026, at 10 a.m. ET. The latest investor presentation is available at https://ir.prenetics.com.

Prenetics positioned itself as a lean IM8 platform, retaining CircleDNA as a side asset. "Our transition towards quarterly subscriptions has delivered a meaningful acceleration in performance," the statement said, with new average order values at $233 so far this year.